Geri
TC Biopharm (Holdings) PLC (TCBPY) Fiyatı
TCBPY Hisse Senedi Fiyat Grafiği
TCBPY Kazanmak
TC Biopharm (Holdings) PLC
$0.1
0%
$0
Kapanışta: Jan 16, 16:00:00 GMT-5
$0.1
0%
$0
Sonrası Piyasa: Jan 16, 20:00:00 GMT-5
Henüz Veri YokEarnings FAQ
TCBPY'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
TC Biopharm (Holdings) PLC TCBPY'ün son çeyrekteki geliri nasıl performans gösterdi?
TC Biopharm (Holdings) PLC'in gelir tahmini nedir?
TC Biopharm (Holdings) PLC'in kazanç kalite puanı nedir?
TC Biopharm (Holdings) PLC kazançlarını ne zaman rapor eder?
TC Biopharm (Holdings) PLC'in beklenen kazançları nelerdir?
TC Biopharm (Holdings) PLC kazanç beklentilerini aştı mı?
Önemli İstatistikler
Önceki Kapanış
$0.1001
Açılış fiyatı
$0.1001
Günün Aralığı
$0.1001 - $0.1001
52 haftalık aralık
$0.03 - $9
İşlem hacmi
--
Ort.Hacim
14.9K
EPS (TTM)
-7.34
Dividend yield
--
Piyasa Değeri
$1.0M
TCBPY nedir?
TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company employs 39 full-time employees The company went IPO on 2022-02-23. The firm is conducting two investigator-initiated clinical trials for its unmodified GD-T cell product line - phase IIb/III pivotal trial in treatment of AML using its allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product candidate, OmnImmune is an unmodified allogeneic GD-T cell product, being initially used for the treatment of AML. Its pre-clinical stage program is focused on developing CAR-modified allogeneic GD-T cell products targeting solid and hematological indications. The company has an Israeli patent and Japanese patent applications covering the method of preparing and using GD-T cells in the allogeneic treatment of subjects suffering from viral, fungal and protozoal infections or cancer.
Özellikler
Ticaret Stratejileri
Kaynaklar
© 2025 Finture Development Limited. All rights reserved